Division of Cardiology, Department of Cardiothoracic Sciences, Second University of Naples, Monaldi Hospital, Via L. Bianchi 8013- Naples, Italy.
Curr Pharm Biotechnol. 2012 Jan;13(1):4-16. doi: 10.2174/138920112798868764.
Myocardial infarction (MI) and stroke are relevant clinical issues in Western Countries for morbidity and mortality. In the last decades, great interest has been paid to the identification of non-traditional risk factors for a better stratification of patients and to recognize those at higher risk, who might particularly benefit from a more aggressive approach. In this field, C-reactive protein (CRP) is the most extensively studied novel marker, since it seems related to several stages of atherogenesis, from its beginning to clinical events (i.e. acute coronary syndromes - ACS). Among its possible pathogenetic role both in coronary artery disease (CAD) and ischemic stroke, several studies have shown that CRP could be used to predict first ever MI and stroke in healthy subjects, as well as outcome in acute settings. Moreover, a decrease of CRP levels can be achieved by several therapies, first of all statins, and this seems to be associated with a better outcome. Then a possible role for CRP to guide treatment of patient with ACS and stroke has been claimed and need to be specifically addressed by large randomized controlled trials.
心肌梗死（MI）和中风是西方国家发病率和死亡率相关的临床问题。在过去几十年中，人们对非传统危险因素的研究产生了浓厚的兴趣，以便更好地对患者进行分层，并识别出那些风险更高的患者，他们可能特别受益于更积极的治疗方法。在这一领域，C 反应蛋白（CRP）是研究最多的新型标志物，因为它似乎与动脉粥样硬化形成的几个阶段有关，从开始到临床事件（即急性冠状动脉综合征 - ACS）。在冠心病（CAD）和缺血性中风的可能发病机制中，多项研究表明，CRP 可用于预测健康受试者首次发生 MI 和中风，以及急性发作时的结局。此外，多种治疗方法可降低 CRP 水平，首先是他汀类药物，这似乎与更好的结局有关。因此，CRP 可能在指导 ACS 和中风患者的治疗中发挥作用，需要通过大型随机对照试验来专门研究。
